ABEONA THERAPEUT. DL-01 - Asset Resilience Ratio
ABEONA THERAPEUT. DL-01 (PCJ) has an Asset Resilience Ratio of 51.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PCJ current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ABEONA THERAPEUT. DL-01's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PCJ total assets.
Liquid Assets Composition Over Time
This chart breaks down ABEONA THERAPEUT. DL-01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of ABEONA THERAPEUT. DL-01 for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €112.97 Million | 51.45% |
| Total Liquid Assets | €112.97 Million | 51.45% |
Asset Resilience Insights
- Very High Liquidity: ABEONA THERAPEUT. DL-01 maintains exceptional liquid asset reserves at 51.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ABEONA THERAPEUT. DL-01 Industry Peers by Asset Resilience Ratio
Compare ABEONA THERAPEUT. DL-01's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ABEONA THERAPEUT. DL-01.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.45% | €112.97 Million ≈ $132.07 Million |
€219.57 Million ≈ $256.70 Million |
-16.82pp |
| 2024-12-31 | 68.27% | €74.36 Million ≈ $86.94 Million |
€108.93 Million ≈ $127.35 Million |
+9.28pp |
| 2023-12-31 | 58.99% | €37.75 Million ≈ $44.14 Million |
€64.00 Million ≈ $74.83 Million |
-0.08pp |
| 2022-12-31 | 59.07% | €37.93 Million ≈ $44.35 Million |
€64.21 Million ≈ $75.07 Million |
+43.89pp |
| 2021-12-31 | 15.19% | €12.09 Million ≈ $14.13 Million |
€79.59 Million ≈ $93.04 Million |
-- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more